Arrowstreet Capital’s Pacira BioSciences PCRX Stock Holding History

Arrowstreet Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-36,966	Closed	-$835K	–	2081
2026 Q1	$835K	Sell	36,966 -16,232	-31%	-$361K	﹤0.01%	1595
2025 Q4	$1.38M	Buy	53,198 +11,405	+27%	+$271K	﹤0.01%	1489
2025 Q3	$1.08M	Buy	41,793 +6,187	+17%	+$152K	﹤0.01%	1580
2025 Q2	$851K	Sell	35,606 -31,982	-47%	-$806K	﹤0.01%	1650
2025 Q1	$1.68M	Sell	67,588 -579,730	-90%	-$13.9M	﹤0.01%	1353
2024 Q4	$12.2M	Sell	647,318 -505,307	-44%	-$8.87M	0.01%	766
2024 Q3	$17.3M	Buy	1,152,625 +1,099,216	+2,058%	+$18.8M	0.01%	574
2024 Q2	$1.53M	Buy	+53,409	New	+$1.52M	﹤0.01%	1138
2017 Q3	–	Sell	-12,000	Closed	-$572K	–	1199
2017 Q2	$572K	Buy	+12,000	New	+$557K	﹤0.01%	860
2015 Q1	–	Sell	-46,160	Closed	-$4.09M	–	1171
2014 Q4	$4.09M	Sell	46,160 -70,334	-60%	-$6.65M	0.02%	501
2014 Q3	$11.3M	Buy	116,494 +90,908	+355%	+$8.84M	0.06%	256
2014 Q2	$2.35M	Buy	+25,586	New	+$1.95M	0.01%	549

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's PCRX Position: Q2 2026 in Review

Arrowstreet Capital sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 36,966 shares — an estimated $835K sold.

Arrowstreet Capital first reported a position in PCRX in Q2 2014 and held it in 12 quarters. The position peaked at $17.3M in Q3 2024. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Arrowstreet Capital reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
Arrowstreet Capital sold 36,966 Pacira BioSciences shares in Q2 2026, an estimated $835K.
Arrowstreet Capital first reported a position in Pacira BioSciences in Q2 2014 and held it in 12 quarters.
Arrowstreet Capital's Pacira BioSciences position peaked at $17.3M in Q3 2024.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.